Cargando…

Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy

BACKGROUND: The clinical utility of plasma tumor mutational burden (pTMB) requires further validation. Herein, the pTMB and genetic alterations were investigated as predictive biomarkers for anti-PD-1 monotherapy outcome in metastatic non-small cell lung cancer (NSCLC). METHODS: The GuardantOMNI pan...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Jii Bum, Park, Hyung Soon, Choi, Su Jin, Heo, Seong Gu, An, Ho Jung, Kim, Hye Ryun, Hong, Min Hee, Lim, Sun Min, Chang, Kyle, Quinn, Katie, Odegaard, Justin, Shim, Byoung Yong, Cho, Byoung Chul
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	SAGE Publications 2022
Materias:	Genomic Biomarkers in Cancer Immunotherapy
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9761799/ https://www.ncbi.nlm.nih.gov/pubmed/36544541 http://dx.doi.org/10.1177/17588359221141761

Ejemplares similares

Tumor mutational burden predicts the efficacy of pembrolizumab monotherapy: a pan-tumor retrospective analysis of participants with advanced solid tumors
por: Cristescu, Razvan, et al.
Publicado: (2022)

Biologic subtypes of melanoma predict survival benefit of combination anti-PD1+anti-CTLA4 immune checkpoint inhibitors versus anti-PD1 monotherapy
por: Rose, April A N, et al.
Publicado: (2021)

High tumor mutational burden predicts favorable response to anti-PD-(L)1 therapy in patients with solid tumor: a real-world pan-tumor analysis
por: Jung, Jaeyun, et al.
Publicado: (2023)

Tumor DNA methylation profiles correlate with response to anti-PD-1 immune checkpoint inhibitor monotherapy in sarcoma patients
por: Starzer, Angelika M, et al.
Publicado: (2021)

Establishing guidelines to harmonize tumor mutational burden (TMB): in silico assessment of variation in TMB quantification across diagnostic platforms: phase I of the Friends of Cancer Research TMB Harmonization Project
por: Merino, Diana M, et al.
Publicado: (2020)

Characterization of tumor mutation burden, PD-L1 and DNA repair genes to assess relationship to immune checkpoint inhibitors response in metastatic renal cell carcinoma
por: Labriola, Matthew Kyle, et al.
Publicado: (2020)

High levels of chromosomal aberrations negatively associate with benefit to checkpoint inhibition in NSCLC
por: Frigola, Joan, et al.
Publicado: (2022)

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
por: Zheng, Ming
Publicado: (2022)

Mutation burden-orthogonal tumor genomic subtypes delineate responses to immune checkpoint therapy
por: Takamatsu, Shiro, et al.
Publicado: (2022)

Improving selection of patients with metastatic colorectal cancer to benefit from cetuximab based on KIR genotypes
por: Manzanares-Martin, Barbara, et al.
Publicado: (2021)

Oncogene-specific differences in tumor mutational burden, PD-L1 expression, and outcomes from immunotherapy in non-small cell lung cancer
por: Negrao, Marcelo V, et al.
Publicado: (2021)

Biological and technical factors in the assessment of blood-based tumor mutational burden (bTMB) in patients with NSCLC
por: Schuurbiers, Milou, et al.
Publicado: (2022)

Computational image features of immune architecture is associated with clinical benefit and survival in gynecological cancers across treatment modalities
por: Azarianpour, Sepideh, et al.
Publicado: (2022)

Correlates of clinical benefit from immunotherapy and targeted therapy in metastatic renal cell carcinoma: comprehensive genomic and transcriptomic analysis
por: Dizman, Nazli, et al.
Publicado: (2020)

Predicting response to immunotherapy in advanced non-small-cell lung cancer using tumor mutational burden radiomic biomarker
por: He, Bingxi, et al.
Publicado: (2020)

Spatial meta-transcriptomics reveal associations of intratumor bacteria burden with lung cancer cells showing a distinct oncogenic signature
por: Wong-Rolle, Abigail, et al.
Publicado: (2022)

Additive effects of variants of unknown significance in replication repair-associated DNA polymerase genes on mutational burden and prognosis across diverse cancers
por: Ying, Jieer, et al.
Publicado: (2021)

Massive PD-L1 and CD8 double positive TILs characterize an immunosuppressive microenvironment with high mutational burden in lung cancer
por: Zhang, Libin, et al.
Publicado: (2021)

Dissecting tumor lymphocyte infiltration to predict benefit from immune-checkpoint inhibitors in metastatic colorectal cancer: lessons from the AtezoT RIBE study
por: Moretto, Roberto, et al.
Publicado: (2023)

Real-world pan-cancer landscape of frameshift mutations and their role in predicting responses to immune checkpoint inhibitors in cancers with low tumor mutational burden
por: Florou, Vaia, et al.
Publicado: (2023)

Influence of tumor mutational burden, inflammatory gene expression profile, and PD-L1 expression on response to pembrolizumab in head and neck squamous cell carcinoma
por: Haddad, Robert I, et al.
Publicado: (2022)

Tumor mutational burden assessment in non-small-cell lung cancer samples: results from the TMB(2) harmonization project comparing three NGS panels
por: Ramos-Paradas, Javier, et al.
Publicado: (2021)

NKG2A and PD-L1 expression panel predicts clinical benefits from adjuvant chemotherapy and PD-L1 blockade in muscle-invasive bladder cancer
por: Yan, Sen, et al.
Publicado: (2022)

Plasma cell marker, immunoglobulin J polypeptide, predicts early disease-specific mortality in HPV+ HNSCC
por: Gui, Shanying, et al.
Publicado: (2021)

Extensive plasma proteomic profiling revealed receptor activator of nuclear factor kappa-Β ligand (RANKL) as emerging biomarker of nivolumab clinical benefit in patients with metastatic renal cell carcinoma
por: Simonetti, Sonia, et al.
Publicado: (2022)

Cancer immune profiling unveils biomarkers, immunological pathways, and cell type score associated with glioblastoma patients’ survival
por: Moreno, Daniel Antunes, et al.
Publicado: (2022)

Prediction of immunotherapy efficacy and immunomodulatory role of hypoxia in colorectal cancer
por: Zheng, Zhuangzhuang, et al.
Publicado: (2022)

Correlation of preclinical and clinical biomarkers with efficacy and toxicity of cancer immunotherapy
por: Zheng, Lin-Peng, et al.
Publicado: (2023)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
por: He, Jie, et al.
Publicado: (2023)

Visceral adiposity and systemic inflammation in the obesity paradox in patients with unresectable or metastatic melanoma undergoing immune checkpoint inhibitor therapy: a retrospective cohort study
por: Lee, Ji Hyun, et al.
Publicado: (2022)

Single-cell RNA sequencing reveals distinct cellular factors for response to immunotherapy targeting CD73 and PD-1 in colorectal cancer
por: Kim, Miok, et al.
Publicado: (2021)

Immunogenomic determinants of tumor microenvironment correlate with superior survival in high-risk neuroblastoma
por: Bao, Riyue, et al.
Publicado: (2021)

Machine learning-based integration develops a metabolism-derived consensus model for improving immunotherapy in pancreatic cancer
por: Guo, Yongdong, et al.
Publicado: (2023)

Neoadjuvant chemoradiation alters biomarkers of anticancer immunotherapy responses in locally advanced rectal cancer
por: Seo, Incheol, et al.
Publicado: (2021)

CMTM6 and PD-L1 coexpression is associated with an active immune microenvironment and a favorable prognosis in colorectal cancer
por: Peng, Qi-Hua, et al.
Publicado: (2021)

Oncogenic states dictate the prognostic and predictive connotations of intratumoral immune response
por: Roelands, Jessica, et al.
Publicado: (2020)

Prognostic value of immune score in nasopharyngeal carcinoma using digital pathology
por: Wang, Ya-Qin, et al.
Publicado: (2020)

Tumor microenvironment evaluation promotes precise checkpoint immunotherapy of advanced gastric cancer
por: Zeng, Dongqiang, et al.
Publicado: (2021)

Early toxicity and clinical outcomes after chimeric antigen receptor T-cell (CAR-T) therapy for lymphoma
por: Brammer, Jonathan E, et al.
Publicado: (2021)

Neutrophil expansion defines an immunoinhibitory peripheral and intratumoral inflammatory milieu in resected non-small cell lung cancer: a descriptive analysis of a prospectively immunoprofiled cohort
por: Mitchell, Kyle G, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_0atbnqbg5dc636prquiri4rd2j